Since 2008, Ms. Caplan has been CEO of Kamedis, a company focused on utilising plant extracts for dermatology purposes. From 2004 to 2007, Ms. Caplan was CEO of GammaCan, a company focused on the use of immunoglobulins for the treatment of cancer. During the previous five years, Ms. Caplan has been a director of the following companies: Opticul Ltd., a company involved with optic based bacteria classification; Inmotion Ltd., a company involved with self-propelled disposable colonoscopies; Nehora Photonics Ltd., a company involved with non-invasive blood monitoring; Ocure Ltd., a company involved with wound management; Eve Medical Ltd., a company involved with hormone therapy for menopause and PMS; and Biotech Investment Corp., a company involved with prostate cancer diagnostics. Ms. Caplan has a M.Sc. in biomedical engineering from Tel-Aviv University specialised in signal processing; management for engineers from Tel-Aviv University specialised in business development; and a B.Sc. in mechanical engineering from the Technion Institute of Technology specialised in software and CAD systems.

Dr. Jay has more than 30 years of private equity experience.  Prior to founding Great Point Partners in 2003, he was for 11 years a General Partner and the head of the health care group at J. H. Whitney & Co., an investment firm with over $6 billion in private equity, subordinated debt and hedge funds under management.  Dr. Jay has led numerous private equity investments and has been the chairman or a member of the boards of numerous companies including AdvancePCS (ADVP), Axiom, Biotronic NeuroNetwork, Clinical Supplies Management, Concentra Managed Care (CCMC), Cytovance Biologics, Eon Labs (ELAB), which was acquired by Novartis, Equian, MaSTherCell, Softbox Systems, Symbion (SYMB), Valenz and U.S. Bioservices.  Dr. Jay received his B.A. magna cum laude and his M.D. with honors from the six-year B.A./M.D. program at the Boston University School of Medicine and an M.B.A. from the Harvard Business School.  He is on the Dean’s Board of Advisors at the Boston University School of Medicine, the Harvard Business School Health Care Advisory Board and the Harvard University Committee on University Resources.

Darren Head is currently CEO and a board member at MaSTherCell.  He is on the board of GPP III portfolio company BioNova.  Mr. Head was the President and CEO of Cytovance Biologics (“Cytovance”), a former GPP I portfolio company and was a board member of GPP II portfolio company Clinical Supplies Management.  He has over 26 years of biological, device and drug manufacturing experience.  Prior to joining Cytovance, Mr. Head was a Senior Vice President of Worldwide Operations with Immucor.  Prior to Immucor, Mr. Head led Aronex Pharmaceuticals manufacturing and clinical supply operations in late Phase 3 programs. He holds a B.S. in biology and attended the executive M.B.A. program at Texas A&M.

Dr. Mazanet trained in medicine/oncology at the Brigham and Women’s Hospital and the Dana-Farber Cancer Institute before joining Amgen, Inc to lead clinical development in the early 1990s. After moving to public equity investing in 1998, she has been involved in specialty pharma and biotechnology as an Investor, Director and Strategic Advisor.

Mr. Rhodes has more than 11 years of private equity experience and joined Great Point Partners in 2006.  He is currently a board member of Axiom, Bionova, Corrona, MaSTherCell, Softbox Systems and Valenz.  Mr. Rhodes was previously a board member of Autism Learning Partners, Cytovance Biologics and Equian.  Prior to joining Great Point Partners, he was an investment banking analyst in Wachovia Securities’ health care group, where he focused on mergers and acquisitions, private placements and public offerings of equity, fixed income and convertible securities.  Mr. Rhodes earned a B.S. in business administration cum laude from Washington and Lee University.

Prior to joining Great Point Partners in 2015, Mr. Hjerpe graduated from the University of Notre Dame with a M.S. in accountancy and a B.B.A in finance. He had completed internships at Sandler O’Neill & Partners, a boutique investment bank, and KPMG where he focused on financial due diligence consulting for private equity clients.

Mark S. Cohen is a Founder, Senior Partner and Chair of the Life Science Practice Group at Pearl Cohen Zedek Latzer Baratz, LLP. Pearl Cohen has offices in New York, Boston, Los Angeles, London and Israel. He is admitted to the New York bar. He is a registered patent attorney in the United States experienced in patent prosecution in the pharmaceutical, chemical, biological and medical device area. He is well versed in various aspects of patent prosecution, intellectual property management, strategic advise, technology assessment, commercial transactions, and licensing matters. He has been involved in large due diligence matters; infringement, validity, and patentability opinions; European patent opposition proceedings; and enforcement matters. His clients that he represents range from start-up companies to Fortune 500 companies. Mark Cohen was named to New York Metro Super Lawyers for 2019 as a Top Rated Intellectual Property Lawyer in New York.

Mark Cohen was Vice Chairman of Akari Therapeutics, Plc. (NASDAQ: AKTX) an emerging biopharmaceutical company that is developing anti-complement and anti-inflammatory molecules as life-transforming treatments for a wide range of severe and orphan autoimmune and inflammatory diseases.

Denis Bedoret joined MaSTherCell in October 2016 as Chief Business and Administration Officer. He was then appointed as General Manager in January 2017 with the ambition to pursue the global development of MaSTherCell’s activities. He previously held the position of COO at Quality Assistance, a leading European analytical CRO where he was also a member of the board of Directors. Denis previously served as Engagement Manager at McKinsey & Company, focusing on (Bio-)pharmaceutical projects. Through those experiences, Denis has gained strong expertise in biologicals, FDA and EMA regulations as well as team management. Denis holds a degree in veterinary Medicine, a Ph.D. in Life Sciences from ULg and a postdoc in Immunology from Harvard Medical School.

With over 15 years of experience in the biopharmaceutical industry and three years in the food industry, Eric’s main areas of expertise are people and field management. At GSK Belgium, he was a significant player in vaccine development, industrialization, process transfer and manufacturing of cell culture processes, while at Baxter Switzerland he developed his cGMP expertise in an FDA approved facility, where he was in charge of large-scale recombinant FVIII manufacturing. Eric started his own consulting company in 2006 working with various SMEs where he applied his experience in facility building, team building and coaching, as well as organizational start-ups. He was in charge of Operations at ARTELIS-ATMI, focusing on the development of disposable bioreactors. Eric holds an engineering degree from the Université de Gembloux, Belgium (FSAGx) and joined MaSTherCell in September 2012.

Gisèle Deblandre graduated from the Université Libre de Bruxelles, Belgium, and holds a Ph.D. in Molecular and Cell Biology. Gisèle ‘s career spans 17 years in R&D in life sciences, with strong expertise in cell biology and mechanisms of cell differentiation. After six years in developmental biology at the Salk Institute (San Diego, California), she managed the DevGen’s drug discovery platform, before becoming Scientific Director for the Wallonia Life Sciences cluster, BioWin. As Director of Development with Cardio3 Biosciences (Mont-Saint-Guibert, Belgium), she managed the R&D department and led the development and validation of release testing assays of the company’s lead product C-Cure, autologous cell therapy for the treatment of chronic heart failure in phase II clinical trial. Gisèle is holding the post of Director of Project Management at MaSTherCell.

Elodie took a Master in Biology at the University of Pisa, supplemented by an HR diploma obtained at ICHEC (Brussels Management School). Subsequently, she worked as Office and Account Manager for an IT leasing company and for 5 years at Kelly Scientific Resources. As Manager of the Belgian Branch of Kelly Scientific, Elodie has developed extensive contacts across the scientific sector leading a team and recruiting scientists for pharmaceutical/biotech companies of all sizes. Since 2012, she has joined the team of MaSTherCell as Human Resources Manager and contributed to its growing development. In addition, she is also leading the administrative responsibilities of the company.

Jean-François is a French engineer graduated from the National Institute of Applied Science of Toulouse. He has been working in the Biotech industry for the past 23 years including 12 years within GSK Vaccines in Rixensart. Over this long period, he was involved in the development and scale-up of different industrial processes based on mammalian cell lines to produce recombinant protein, vaccines, viral vectors with a strong focus on implementing new technologies while keeping an end-to-end vision on all aspect of manufacturability.

Coming soon.

David joined the MaSTherCell US team as General Manager and Vice President of Operations in mid-2019. David brings more than 30 years of pharma/biopharma CDMO experience, with the past 20 years in senior leadership positions. With a passion for developing organizations, implementing business strategy and enhancing the client experience, David is charged with growing the US operational capability.

A graduate of the Royal Society Chemistry (Huddersfield, UK), David previously held the positions of General Manager, Avecia’s Early Phase Delivery business (UK), Vice President Operations, Codexis Inc (Redwood City, California) and Vice President of Supply Chain and Biomanufacturing at Therapure Bio (Ontario, Canada).

Coming soon.